Tempus is set to expand its precision oncology and minimal residual disease (MRD) capabilities after signing a definitive agreement to acquire Personalis for about $1.5 billion. Under the terms, Personalis shareholders will receive $16.25 per share in Tempus stock, a roughly 6% premium, valuing the transaction at approximately $1.5 billion enterprise value, net of Tempus’ existing ownership. The companies say they have previously worked together, including a commercialization partnership for Personalis’ NeXT Personal MRD assay. Tempus expects the deal to close late this year or early next, subject to shareholder approval and regulatory clearances. Personalis also reported preliminary second-quarter revenue of $22.4 million and 10,384 clinical tests delivered, underscoring momentum in test volumes. For biopharma partners, the combination targets increased biomarker discovery and personalized cancer care through the integration of Personalis’ MRD technology with Tempus’ multimodal data and AI platform.